TOP > 外国特許検索 > METHOD FOR EVALUATING SIDE-EFFECT ONSET RISK IN ANTICANCER DRUG TREATMENT, INCLUDING DETECTING MUC4 GENE POLYMORPHISM

METHOD FOR EVALUATING SIDE-EFFECT ONSET RISK IN ANTICANCER DRUG TREATMENT, INCLUDING DETECTING MUC4 GENE POLYMORPHISM

外国特許コード F150008193
掲載日 2015年3月24日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2014JP054796
国際公開番号 WO 2014133055
国際出願日 平成26年2月27日(2014.2.27)
国際公開日 平成26年9月4日(2014.9.4)
優先権データ
  • 特願2013-041305 (2013.3.1) JP
発明の名称 (英語) METHOD FOR EVALUATING SIDE-EFFECT ONSET RISK IN ANTICANCER DRUG TREATMENT, INCLUDING DETECTING MUC4 GENE POLYMORPHISM
発明の概要(英語) The purpose of the present invention is to provide an evaluation method and evaluation kit for evaluating the risk of onset of diffuse alveolar damage due to such factors as anticancer drug administration. The purpose of the present invention is also to provide a method for evaluating the risk of onset of side effects in anticancer drug treatment. An evaluation method and evaluation kit for evaluating the risk of onset of diffuse alveolar damage, including detecting gene polymorphism present in the MUC4 gene. A method for evaluating the risk of onset of side effects in anticancer drug treatment, including detecting gene polymorphism present in the MUC4 gene of a patient scheduled for anticancer drug administration.
従来技術、競合技術の概要(英語) BACKGROUND ART
(Generic name: gefitinib) or Tarceva Iressa (general name: erlotinib) such as anti-cancer drug is, referred to as diffuse alveolar disorders may cause a serious side-effects. In addition, also in acute exacerbations of idiopathic pulmonary fibrosis, diffuse alveolar disorders referred to may cause a serious side-effects. Diffuse alveolar disorders, show resistance to treatment, and the recurrent, repeated exacerbations during treatment further deteriorated at an early stage for severe, very where attention is needed which is one of the symptoms.
Such diffuse alveolar disorder is, to the development of a high frequency in Japanese is reported (non-patent document 1). For example, is the case in accordance with the frequency of the check at overseas gefitinib is in contrast to the 0.3%, 3.98% and 10 times or more in the frequency of the Japanese and the frequency. In addition, is the case in accordance with erlotinib, investigation PRTDRV Asian 0.2% and on the other hand, in the investigation intended Japanese and 2.7%, also 10 and the frequency of times or more. In addition, in patients with idiopathic pulmonary fibrosis, acute exacerbations occur to a higher frequency than other countries, high mortality has been reported (non-patent document 2). Japanese deaths is diffuse alveolar injury, is estimated to reach several thousand years been. However, not limited to Japanese, overseas as well, even aside from the frequency, drug's side-effects have died is that there is a case, a serious problem.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • SAITAMA MEDICAL UNIVERSITY
  • 発明者(英語)
  • HAGIWARA, Koichi
  • MIYAZAWA, Hitoshi
  • SHIIHARA, Jun
  • TANAKA, Tomoaki
  • INOUE, Yoshiaki
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN TD TG

PAGE TOP

close
close
close
close
close
close